Investor's Business Daily on MSN
IBD rating upgrades: Rogers Communications B shows improved price strength
A Relative Strength Rating upgrade for Rogers Communications B shows improving technical performance. Will it continue?
LGBTQ+ individuals with inflammatory bowel disease experience multiple gaps and inequities in care when managing their ...
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
Investor's Business Daily on MSN
Stock market winners dominate this IBD earnings screen in spades
With fourth-quarter earnings season in full swing, check out this screen of stock market leaders with top fundamentals.
Among patients with IBD in self reported clinical remission, habitual meat intake may affect the risk for flares in those with ulcerative colitis, but not in those with Crohn's disease.
A hidden immune cascade linking the gut and bone marrow may explain how IBD turns inflammation into colon cancer.
For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense ...
SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...
Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results